» Articles » PMID: 11313155

D(2) and 5HT(2A) Receptor Occupancy of Different Doses of Quetiapine in Schizophrenia: a PET Study

Overview
Publisher Elsevier
Specialties Pharmacology
Psychiatry
Date 2001 Apr 21
PMID 11313155
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Quetiapine is a novel antipsychotic agent with many atypical features, including low D(2) and higher 5HT(2A) affinity in vitro, low propensity to induce extra-pyramidal side effects and minimal effects on prolactin levels. The purpose of this study was to investigate, using positron emission tomography (PET), the relationship between plasma concentrations of different doses of quetiapine and occupancy of D(2) and 5HT(2A) receptors in schizophrenic patients.

Methods: Five patients were treated with quetiapine (titrated to 750 or 450 mg/day) for 28 days, subsequently reduced weekly in a descending-dose schedule. Dopamine D(2) and 5HT(2A) occupancies were determined using [(11)C] raclopride and [(11)C] N-methylspiperone as ligands, respectively, and PET imaging.

Results: Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day. At lower dose levels no occupancy could be determined. Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively. No EPS emerged during the trial and most of the pre-trial EPS resolved during the study.

Conclusions: In clinically effective doses, quetiapine induced low occupancy at D(2) receptors, which is consistent with atypical antipsychotics such as clozapine, and probably explains the lack of EPS observed in this trial. Correlations between receptor occupancy and plasma concentrations of quetiapine could not be calculated, although receptor occupancy increased with higher plasma concentrations for the 450 and 750 mg doses.

Citing Articles

Psilocybin for Depression: From Credibility to Feasibility, What's Missing?.

Munafo A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678564 PMC: 9861656. DOI: 10.3390/ph16010068.


Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.

Hopkins S, Wilkinson S, Corriveau T, Nishikawa H, Nakamichi K, Loebel A Clin Pharmacol Ther. 2021; 110(3):808-815.

PMID: 33961287 PMC: 8453756. DOI: 10.1002/cpt.2282.


"Fake it till You Make it"! Contaminating Rubber Hands ("Multisensory Stimulation Therapy") to Treat Obsessive-Compulsive Disorder.

Jalal B, McNally R, Elias J, Potluri S, Ramachandran V Front Hum Neurosci. 2020; 13:414.

PMID: 31998095 PMC: 6962184. DOI: 10.3389/fnhum.2019.00414.


Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H Neuropsychopharmacology. 2019; 45(5):887-901.

PMID: 31770770 PMC: 7075912. DOI: 10.1038/s41386-019-0573-7.


Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia.

Amato D, Kruyer A, Samaha A, Heinz A Front Psychiatry. 2019; 10:314.

PMID: 31214054 PMC: 6557273. DOI: 10.3389/fpsyt.2019.00314.